CMBI has issued a research report noting a 14.1% year-to-date decline in the MSCI China Health Care Index, significantly trailing the MSCI China Index by 31.25%. This recent market volatility underscores the pharmaceutical sector’s notable resilience. With overseas interest rate cuts and improvements in China’s macroeconomic landscape, the pharmaceutical industry is poised to outperform the broader market.
Additionally, new health insurance negotiations are set to commence in China. While there are concerns regarding the financial balance of health insurance funds, the policy direction to support innovative drugs through these funds remains unchanged. CMBI particularly favors companies such as WuXi AppTec, BeiGene, Innovent Biologics, SKB Bio-B, Giant Biogene, 3SBIO, and Mindray Bio-Medical.
Related topics:
